TORONTO, CANADA — (July 12, 2021) Dalriada is pleased to announce a strategic collaboration with Antibe Therapeutic to develop new drug candidates that target inflammation in a wide range of health conditions and fortify Antibe’s intellectual property position related to their novel hydrogen sulfide platform.
Antibe’s first candidates for screening address inflammatory bowel disease (“IBD”), a condition affecting more than three million North American adults. Dalriada’s efforts are being directed towards the development of fresh IP for existing pipeline drugs to lengthen the duration of patent and market protection. Antibe will retain ownership rights to any new IP.
“With the increasing recognition of inflammation’s central role in many diseases, we see the profound potential of Antibe’s revolutionary anti-inflammatory platform. Dalriada’s Turn-Key model is specifically designed to enable rapid expansion of therapeutic pipelines and accelerate value creation for our partners’ programs.” Said Diana Kraskouskaya, CEO Dalriada. “We are excited to commit our resources to this undertaking in collaboration with Antibe’s world-renowned scientists and expert commercial team.”
A specialist in the development of small-molecule drugs from initial discovery to development candidate nomination and management of IND-enabling studies, Dalriada efforts will extend medicinal chemistry capabilities and accelerate screening, selection and advancement of drug candidates with Antibe. The Dalriada team comprises of more than 50 scientists, including world-class experts in medicinal chemistry, bioanalytical chemistry, biochemistry, proteomics and computational chemistry.
“The robust data from the otenaproxesul’s extensive animal studies and human trials have highlighted the broad therapeutic and commercial potential of our drug platform,” commented Dan Legault, Antibe’s CEO. “As we prepare for otenaproxesul’s Phase III program, our strong balance sheet also enables us to tap Dalriada’s scientific expertise and throughput capacity to further our pipeline expansion strategy and IP position – efficiently and cost-effectively. This collaboration also leverages the projects already underway with our U.S. university-based chemistry group.”